Comparison between the European and North American protocols for diagnosis of malignant hyperthermia susceptibility in humans

Anesthesia and Analgesia

Volumn 88, Issue 5, 1999, Pages 1155-1160

  Islander, Gunilla ^a   Twetman, Eva Ranklev ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHESIA COMPLICATION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENERAL ANESTHESIA; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; VASTUS LATERALIS MUSCLE;

CAFFEINE; HALOTHANE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; SENSITIVITY AND SPECIFICITY;

EID: 0032924940     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199905000-00035     Document Type: Article

References (17)

1. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984;56:1267-9.
2. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997;41:955-66.
3. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989;69:511-5.
4. Ording H, Bendixen D. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Eur J Anaesthesiol 1992;9:367-76.
5. Fletcher JE, Conti PA, Rosenberg H. Comparison of North American and European Malignant Hyperthermia Group halothane contracture testing protocols in swine. Acta Anaesthesiol Scand 1991;35:483-7.
6. Allen GC, Larach MG, Kunselman AR, et al. The sensitivity and specificity of the caffeine-halothane contracture test. Anesthesiology 1998;88:579-88.
7. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-9.
8. Islander G, Bendixen D, Ranklev-Twetman E, Ording H. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands. Acta Anaesthesiol Scand 1996;40:579-84.
9. Monnier N, Procaccio V, Stieglitz P, et al. Malignant hyperthermia susceptibility is associated with a mutation in the α1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997;60:1316-25.
10. Islander G, Ranklev Twetman E. Evaluation of anaesthesia in malignant hyperthermia negative patients. Acta Anaesthesiol Scand 1995;39:819-21.
11. Ording H, Hedengran AM, Skovgaard LT. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol Scand 1991;35: 711-6.
12. Allen GC, Rosenberg H, Fletcher JE. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility. Anesthesiology 1990;72:619-22.
13. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993;79:5-9.
14. Wedel DJ, Nelson TE. Malignant hyperthermia: diagnostic dilemma - false-negative contracture responses with halothane and caffeine alone. Anesth Analg 1994;78:787-92.
15. Lin JP, Brown JK, Walsh EG. Physiological maturation of muscles in childhood. Lancet 1994;343:1386-9.
16. Brooke MH, Engel WK. The histographic analysis of human muscle biopsies with regard to fiber types. 4. Children's biopsies. Neurology 1969;19:591-605.
17. Pessah IN, Lynch C III, Gronert GA. Complex pharmacology of malignant hyperthermia [editorial]. Anesthesiology 1996;84: 1275-9.